Vered Bisker-Leib

Vered Bisker-Leib, PhD, MBA joined Compass in 2017 as Chief Business Officer bringing 20 years of corporate development, strategy, fundraising, licensing, and M&A transaction expertise gained through her experience at top tier pharmaceutical and biotech companies. She was promoted to Chief Operating Officer in 2019 and to President and Chief Operating Officer in 2020. In this role, Vered led the transition of Compass from private to public including raising more than $200 million in public funding in less than 18 months. In 2021, Vered identified and led the acquisition of TRIGR Therapeutics in a stock-for-stock transaction, which resulted in the addition of Compass’ flagship program, CTX-009, to its pipeline. Dr. Bisker-Leib is also a member of the Board of Directors of Ayala Pharmaceuticals, Inc. (Nasdaq: AYLA).

Before joining Compass, Vered advised Atlas Venture portfolio companies as an entrepreneur-in-residence. Previously, she was Chief Business Officer of Cydan, where she co-founded companies focused on advancing therapies for rare diseases, including Imara, Inc (Nasdaq: IMRA), a company developing a novel therapy for sickle cell disease. Earlier in her career, Vered was a member of Bristol Myers Squibb’s Strategic Transactions Group, where she assumed roles of increasing responsibility across five therapeutic areas – most recently as an Executive Director and Global Head of Business Development for the Cardiovascular and Metabolic franchises. There, Vered led a team responsible for creating and executing business development strategy and facilitated the licensing of pre-clinical and clinical- stage programs from Alder Pharmaceuticals, ZymoGenetics, Amira Pharmaceuticals, Ambrx, Portola, and Amylin Pharmaceuticals, and others.

Vered concurrently earned a PhD in chemical engineering and an MBA from the University of Massachusetts, Amherst, where she was a Lois Pope MBA Scholar. She has a BSc in chemical engineering from the Israel Institute of Technology in Haifa.